Banque Cantonale Vaudoise Has $10.32 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Banque Cantonale Vaudoise decreased its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 20.6% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 63,643 shares of the company's stock after selling 16,486 shares during the period. Banque Cantonale Vaudoise's holdings in Johnson & Johnson were worth $10,315,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD lifted its position in Johnson & Johnson by 16.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 21,834,359 shares of the company's stock worth $3,453,978,000 after buying an additional 3,139,499 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its position in Johnson & Johnson by 10.8% during the second quarter. Massachusetts Financial Services Co. MA now owns 18,780,645 shares of the company's stock valued at $2,744,979,000 after purchasing an additional 1,831,751 shares during the last quarter. Ameriprise Financial Inc. grew its stake in Johnson & Johnson by 5.5% in the second quarter. Ameriprise Financial Inc. now owns 14,374,397 shares of the company's stock valued at $2,100,427,000 after purchasing an additional 754,200 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Johnson & Johnson by 16.2% during the 2nd quarter. Dimensional Fund Advisors LP now owns 13,147,352 shares of the company's stock worth $1,921,565,000 after purchasing an additional 1,829,257 shares in the last quarter. Finally, American Century Companies Inc. lifted its holdings in shares of Johnson & Johnson by 5.8% during the 2nd quarter. American Century Companies Inc. now owns 8,014,213 shares of the company's stock valued at $1,171,357,000 after buying an additional 437,637 shares during the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Price Performance

Shares of Johnson & Johnson stock traded down $1.80 during mid-day trading on Tuesday, reaching $152.97. 8,231,159 shares of the stock were exchanged, compared to its average volume of 7,024,149. The company has a market cap of $368.29 billion, a price-to-earnings ratio of 22.11, a price-to-earnings-growth ratio of 2.74 and a beta of 0.53. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $168.85. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. The firm has a 50-day simple moving average of $161.11 and a 200 day simple moving average of $156.16.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, topping analysts' consensus estimates of $2.21 by $0.21. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The company had revenue of $22.47 billion during the quarter, compared to the consensus estimate of $22.17 billion. During the same period in the previous year, the firm posted $2.66 earnings per share. The company's revenue was up 5.2% on a year-over-year basis. On average, sell-side analysts predict that Johnson & Johnson will post 9.93 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be issued a dividend of $1.24 per share. The ex-dividend date is Tuesday, November 26th. This represents a $4.96 annualized dividend and a yield of 3.24%. Johnson & Johnson's dividend payout ratio is currently 71.78%.

Insider Buying and Selling at Johnson & Johnson

In other news, VP Robert J. Decker sold 5,635 shares of the business's stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the completion of the transaction, the vice president now directly owns 18,973 shares in the company, valued at approximately $3,131,683.38. The trade was a 22.90 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.16% of the company's stock.

Analysts Set New Price Targets

A number of research firms recently commented on JNJ. Royal Bank of Canada increased their price objective on Johnson & Johnson from $178.00 to $181.00 and gave the stock an "outperform" rating in a report on Wednesday, October 16th. Guggenheim raised their price target on shares of Johnson & Johnson from $156.00 to $162.00 and gave the company a "neutral" rating in a report on Wednesday, November 6th. Morgan Stanley upped their price objective on shares of Johnson & Johnson from $169.00 to $175.00 and gave the stock an "equal weight" rating in a report on Wednesday, October 16th. StockNews.com upgraded Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a report on Saturday, September 14th. Finally, Daiwa America lowered Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a report on Tuesday, July 23rd. Seven equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $175.94.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.